All In Biotech

Drug Trial Radar · NCT00235716

A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease

CSP #546 - A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease (TEAM-AD)

Last checked: Nov 20, 2026Latest source record: Jul 23, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 613 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

613

Actual

Start

Aug 2007

Primary completion

Sep 2012

Study completion Oct 2012

Sponsor

Lead sponsor
US Department of Veterans AffairsFederal agency
Sponsor type
Federal agency
Collaborators
Forest Laboratories; dsm-firmenich Switzerland AG
First posted
Oct 10, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Factorial
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether alpha-tocopherol, memantine (Namenda), or the combination will significantly delay clinical progression in mild to moderately demented patients with Alzheimer's disease compared to placebo.

Conditions

  • Alzheimer's Disease

Interventions

  • dl-alpha-tocopherolDrug

    Alpha-tocopherol will be given as an oral dose of 1000 IU twice a day (morning and evening). The form of vitamin E that will be used in this study will be hard gel capsules of dl-alpha-tocopheryl acetate ("synthetic") vitamin E.

  • MemantineDrug

    A moderate-affinity NMDA antagonist. Memantine will be titrated over four weeks to a maintenance dose of 10 mg twice a day. During week 1 patients will take one 5-mg memantine tablet in the morning. During week 2 patients will take one 5-mg memantine tablet in the morning and one in the evening. During week 3 patients will take two 5-mg memantine tablets in the morning and one 5-mg tablet in the evening. Beginning with week 4, participants will take four 5-mg tablets daily, two in the morning and two in the evening.

  • dl-alpha-tocopherolDrug

    Alpha-tocopherol will be given as an oral dose of 1000 IU twice a day (morning and evening). The form of vitamin E that will be used in this study will be hard gel capsules of dl-alpha-tocopheryl acetate ("synthetic") vitamin E.

  • MemantineDrug

    A moderate-affinity NMDA antagonist. Memantine will be titrated over four weeks to a maintenance dose of 10 mg twice a day. During week 1 patients will take one 5-mg memantine tablet in the morning. During week 2 patients will take one 5-mg memantine tablet in the morning and one in the evening. During week 3 patients will take two 5-mg memantine tablets in the morning and one 5-mg tablet in the evening. Beginning with week 4, participants will take four 5-mg tablets daily, two in the morning and two in the evening.

  • PlaceboDrug

    Matching placebos for dl-alpha-tocopherol and memantine.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Alzheimer's Disease Cooperative Study/Activities of Daily Living (ADCS/ADL) Inventory Change From BaselineTime frame: 6, 12, 18, 24, 30, 36, 42 and 48 months minus baseline
  2. Mini-Mental State Examination Change From BaselineTime frame: 6, 12, 18, 24, 30, 36, 42 and 48 months minus baseline
  3. Alzheimer's Disease Assessment Scale - Cognitive (ADAS-cog) Change From BaselineTime frame: 6, 12, 18, 24, 30, 36, 42 and 48 months minus baseline
  4. Neuropsychiatric Inventory Change From BaselineTime frame: 6, 12, 18, 24, 30, 36, 42 and 48 months minus baseline
  5. Caregiver Activity Survey Change From BaselineTime frame: 6, 12, 18, 24, 30, 36, 42 and 48 months minus baseline

Locations

14 sites in 2 countries. Site status is shown where the registry gives one.

  • VA Medical Center, Bay Pines

    Bay Pines, Florida

  • VA Medical Center, Miami

    Miami, Florida

  • VA Medical Center, Iowa City

    Iowa City, Iowa

  • VA Maryland Health Care System, Baltimore

    Baltimore, Maryland

  • VA Medical Center, Jamaica Plain Campus

    Boston, Massachusetts

  • VA Ann Arbor Healthcare System

    Ann Arbor, Michigan

  • VA Medical Center, Minneapolis

    Minneapolis, Minnesota

  • Salisbury VAMC

    Salisbury, North Carolina

  • VA Medical Center, Cleveland

    Cleveland, Ohio

  • Ralph H Johnson VA Medical Center, Charleston

    Charleston, South Carolina

  • VA North Texas Health Care System, Dallas

    Dallas, Texas

  • VA Puget Sound Health Care System, Seattle

    Seattle, Washington

  • Wlliam S. Middleton Memorial Veterans Hospital, Madison

    Madison, Wisconsin

  • VA Medical Center, San Juan

    San Juan, Puerto Rico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.